Hemab Therapeutics Holdings
- Market cap
- 1.34B
- P/E (TTM)i
- -16.11
- P/Bi
- 2.95
- EPSi
- -1.45
- Div yieldi
- 0.00%
- 52W posi
- 18%
Anonymous reader poll. Unscientific, not investment advice.
Hemab Therapeutics Holdings ended the session at 28.70, up 1.16%. Its market capitalisation is about 1.34B, the #3007 most valuable US-listed company we track. Wall Street's 4-analyst consensus lands on Buy, with a price target averaging 54.25 (+89% from here). Over the past year the stock has ranged from 23.00 to 55.42; it now sits 18% up that band.
✦ StockVane Quant Insights how this is computed
- Mid-pack momentum — held if you own it, not a fresh buy.
- Signal has read HOLD for 1 year.
- Recent price momentum is -8.9% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has risen to 5.7% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is below the 60-day average, a short-term downtrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Price chart
Performance
Key statistics
Price & volume
- Prev close
- 28.37
- Open
- 28.25
- Day range
- 27.38 - 28.98
- Avg price
- 28.26
- Volume
- 377.19K
- Turnover
- 10.66M
- Turnover ratei
- 2.25%
- Volume ratioi
- 0.79
- Amplitudei
- 5.64%
- 52-week rangei
- 23.00 - 55.42
Valuation
- P/Ei
- -19.85
- P/E (TTM)i
- -16.11
- P/Bi
- 2.95
- EPSi
- -1.45
- Book value / shi
- 9.73
- Net profit
- -67.55M
- Net assets
- 454.28M
Share structure
- Market cap
- 1.34B
- Float capi
- 480.73M
- Shares out
- 46.71M
- Float sharesi
- 16.75M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 2026-05-01
48.2% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-1.69M net over the window
Short interest
- Shares short
- 2.64M
- % of floati
- 5.65%
- Days to coveri
- 7.54
- As of
- 2026-09-15
Frequently asked questions
What is the current stock price of Hemab Therapeutics Holdings (COAG)?
Hemab Therapeutics Holdings last traded at 28.70. The quote on this page refreshes every few seconds while US markets are open.
What is Hemab Therapeutics Holdings's market cap?
About 1.34B.
What is the P/E ratio of Hemab Therapeutics Holdings?
The trailing twelve-month P/E is -16.11. The Valuation tab shows it against the stock's own five-year range.
Does Hemab Therapeutics Holdings pay a dividend?
Hemab Therapeutics Holdings does not currently pay a regular dividend.
Is Hemab Therapeutics Holdings a buy according to analysts?
The consensus of 4 analysts is a Buy rating, with an average 12-month price target of 54.25, which implies 89.0% upside from the current price. This is not investment advice.
What is Hemab Therapeutics Holdings's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Hemab Therapeutics Holdings a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.
Quote time 2026-10-08 02:52:22 · For reference only, not investment advice and not tailored to your situation.